{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 210,
  "pageCount": 415,
  "prevPage": 209,
  "nextPage": 211,
  "slideType": "preempt_rebuttal",
  "function": "preempt_rebuttal",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses two charts to illustrate why XR is ineffective for this specific drug profile.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "line_chart",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/210",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-210",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Diazoxide XR formulation rationale lacks credibility",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b2a8-4009bc6b8131",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.5,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "chart",
      "text": "Simulated Plasma Concentration Curves for Diazoxide.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11dc6d83-2976-458c-829a-1ffba57c4f71",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.5,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Comparison of Immediate Release vs Slow Release (XR) concentration over time.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2ce27479-2358-4353-a242-af37104b5264",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.38,
        "x": 0.58,
        "y": 0.22
      },
      "kind": "list",
      "text": "Diazoxide is avidly bound to albumin (>90%) and eliminated in kidney extending its half-life to 30 h (XR form = minimal benefit – may decrease XR bioavailability). Diazoxide already has a slow absorption rate (Tmax of 4 to 6 hours) (XR minimal benefit). Why make a salt form? Proglycem is already >95% absorbed (XR likely to decrease XR bioavailability). Albumin-bound inactive drug is the body's slow-release form (10% circulating at any time) over a long period of time (proglycem half-life = 30 h) (XR minimal benefit). Limited decrease in plasma levels with XR. XR formulation may decrease bioavailability due to unabsorbed fraction reaching the colon (human transit time to colon ~ 10 h). No PK data to evaluate DCCR bioavailability relative to “lower plasma levels” at steady state.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c13cec0-5d9e-498b-858b-a0a905862cfa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital analysis and estimates",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0274f852-2773-485a-8dfd-6421252cddd1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "title",
      "text": "Diazoxide XR formulation rationale lacks credibility",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ae62329-baf7-4eba-bebe-c27df0caf16e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Thus, XR formulations cannot improve PK characteristics of drugs with >24 hours half-life and 95% bioavailability, such as diazoxide.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f30e8f9-4a46-4072-a1ff-2a60f83ecd82",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "SCQA Framework",
      "slug": "scqa-framework",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "c69fc7c5-ee97-4cc6-af99-a500fca25e34",
      "evidence": "The slide presents a clear situation (thus), a complication (XR formulations cannot improve PK characteristics), and an answer (it lacks credibility).",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}